Menus Subscribe Search

Defeating Bacteria From the Inside Out

• April 19, 2012 • 4:03 PM

The world’s most ubiquitous organism could save millions of lives — if only they could get a new tryout.

Bacteriophages, a class of viruses that only attack bacteria, have been controversial ever since their discovery by a brash, young, self-taught researcher named Felix d’Herelle nearly a century ago.

In the 1920s and ’30s, before the advent of antibiotics, doctors using phage therapy reported near miraculous cures for infections, even at the critical stage. The treatments, however, didn’t work in every case, and after the discovery of much more reliable antibiotics, starting with penicillin in the 1940s, phage therapy was ushered off the medical stage in the United States and Western Europe.

Anna Kuchment, an editor at Scientific American, labeled phage therapy The Forgotten Cure in her recent book, in which she says the practice took up residence behind the Iron Curtain where antibiotics were scarce.

Alexander Sulakvelidze, who grew up in Tbilisi, Georgia, says phage therapy was there for him when he was a child. “Everybody took them when they got sick. It was just something you did.”

Although we now take penicillin and its host of antibiotic descendants for granted, scientists say with the emergence of more strains of antibiotic-resistant disease, it may be just a matter of time before we are forced to seek some alternatives, and researchers suggest that phage therapy may be just the ticket. And since the end of the Cold War, word has been trickling out that phage therapy still works.

• • • • • • • • • • • • • • •

Forty times smaller than the bacteria they prey upon, each species of phage hones in on one specific type of bacteria. Finding its target, a phage attaches to its bacterial host and deliver a dose of DNA that converts the bacteria into a factory to make more phages — eating the germ from the inside out.

Phages can be found almost anywhere there is water (including the human nostril); they may be the most common organism on Earth. Mankind is awash in them, says Sulakvelidze, who grew up to be chief science officer for Intralytix, a Baltimore-based manufacturer of phage-based products.

For an effective therapy, proponents note, caregivers need to identify a pathogen precisely, then pick the exact species of phage that attacks it. (Antibiotics can work without knowing the specific bacterium because they attack a broad spectrum of bacteria.) The ability to identify the offending bacteria, although not foolproof, is much improved by genetic analysis and other means not available during 1930s.

Still, well-understood bacterial diseases like shigella, a disease of the digestive tract, make a good starting point for deploying phages. If phage therapy were more widely available, Sulakvelidze said, “and you saved just 10 percent of the 700,000 children killed each year by shigella, it would be mind boggling.”

And while they’re fast acting, beginning the process of breaking down targeted bacteria within minutes of application, when phages are done destroying bacteria they become inactive, he adds.

“There would be no downside to trying [phage therapy],” he argues, “The worst-case scenario would be that it did not work — it’s pretty well established that it could do no harm.”

(Because bacteria can be cagey opponents, Sulakvelidze says it would be best to use a variety of species of phage in a cocktail, to be sure to eliminate both the target strain and any closely related variants that might arise during an infection.)

Too good to be true? In a way.

Phage therapy is not a panacea, Sulakvelidze says. “Baseless claims” made by early enthusiasts helped to diminish phage therapy’s reputation in the past.

For instance, he contrasts shigella with tuberculosis, for which it’s “difficult to imagine” a phage-based treatment. That’s in part because the phage cannot get inside of human cells where TB takes up residence, nor can they easily pursue the TB bacterium to the various parts of the body where it hides out.

• • • • • • • • • • • • • • •

The road to market is not an easy one, and experts say for a new antibiotic getting through the administrative hurdles can take years and cost in the neighborhood of $100 million, with the essential requirement of the double-blind clinical trial.

Dr. Glenn Morris, director of the Emerging Pathogens Institute at the University of Florida, co-founded Intralytix, Inc., with Sulakvelidze. While subsequent applications have gone more smoothly, he said, the U.S. Food and Drug Administration approval process for ListShield, the firm’s first phage-based product targeting listeria in food, took four years to reach the approval stage. Morris says that was “largely because there was no standard channel at the FDA for considering phage-based products.”

Phage preparations, by their nature need to be individualized in order to perform at their best. Ideally, Sulakvelidze says, an appropriate regulatory process would take a non-traditional approach, granting manufacturers the flexibility to mix and match phage combinations to address distinct outbreaks, or individual cases, without having to re-enact the entire clinical trial procedure every time they target a phage against a different bacterium.

Bill Egan, the former acting director of the FDA Office of Vaccine Research and Review, says he can see some logic in that approach. He envisions a process similar to the one used for approving annual influenza vaccines, which allows manufacturers to obtain approval based for new versions of influenza vaccines without the necessity for repeated large-scale clinical trials.

He says after first demonstrating that phage therapy can be performed with safety and efficacy, manufacturers of phage treatments would then need to be able to show they “have a procedure in place to handle the individual outbreak, that they have a way to determine the efficacy of therapy.” And finally they would need to demonstrate that when they put a phage preparation together “that it is effective.”

Although the FDA approval process can be arduous, Egan says, it’s flexible. The agency, “as much as anybody else, wants to see safe and effective products go out on the market.”

Ultimately, Egan says the test of phage therapy will be public acceptance. “The physicians will have their set criteria and patients will have theirs. That happens with any new thing, this happened when generics were first introduced; there was a lot of resistance. Now everybody takes them.”

David Richardson
David Richardson began his journalism career operating a video news service in Washington, D.C., that covered federal agencies and Congress. His film production work has since ranged from postings at the White House to rural villages of Botswana, documenting community-centered HIV prevention programs. He holds a B.A. degree in government from Dartmouth College. He now writes on science, the environment and policy from Baltimore, Md., where he's had some success growing organic produce in a small backyard garden.

More From David Richardson

A weekly roundup of the best of Pacific Standard and PSmag.com, delivered straight to your inbox.

Recent Posts


September 18 • 4:00 PM

Racial Disparity in Imprisonment Inspires White People to Be Even More Tough on Crime

White Americans are more comfortable with punitive and harsh policing and sentencing when they imagine that the people being policed and put in prison are black.



September 18 • 2:00 PM

The Wages of Millions Are Being Seized to Pay Past Debts

A new study provides the first-ever tally of how many employees lose up to a quarter of their paychecks over debts like unpaid credit card or medical bills and student loans.


September 18 • 12:00 PM

When Counterfeit and Contaminated Drugs Are Deadly

The cost and the crackdown, worldwide.


September 18 • 10:00 AM

How Do You Make a Living, Molly Crabapple?

Noah Davis talks to Moly Crapabble about Michelangelo, the Medicis, and the tension between making art and making money.


September 18 • 9:00 AM

Um, Why Are These Professors Creeping on My Facebook Page?

The ethics of student-teacher “intimacy”—on campus and on social media.


September 18 • 8:00 AM

Welcome to the Economy Economy

With the recent introduction of Apple Pay, the Silicon Valley giant is promising to remake how we interact with money. Could iCoin be next?



September 18 • 6:09 AM

How to Build a Better Election

Elimination-style voting is harder to fiddle with than majority rule.


September 18 • 6:00 AM

Homeless on Purpose

The latest entry in a series of interviews about subculture in America.


September 18 • 4:00 AM

Why Original Artworks Move Us More Than Reproductions

Researchers present evidence that hand-created artworks convey an almost magical sense of the artist’s essence.


September 17 • 4:00 PM

Why Gun Control Groups Have Moved Away From an Assault Weapons Ban

A decade after the ban expired, gun control groups say that focusing on other policies will save more American lives.


September 17 • 2:00 PM

Can You Make Two People Like Each Other Just By Telling Them That They Should?

OKCupid manipulates user data in an attempt to find out.


September 17 • 12:00 PM

Understanding ISIL Messaging Through Behavioral Science

By generating propaganda that taps into individuals’ emotional and cognitive states, ISIL is better able motivate people to join their jihad.


September 17 • 10:00 AM

Pulling Punches: Why Sports Leagues Treat Most Offenders With Leniency

There’s a psychological explanation for the weak punishment given to Ray Rice before a video surfaced that made a re-evaluation unavoidable.


September 17 • 9:44 AM

No Innovation Without Migration: Portlandia Is Dying

Build an emerald city. Attract the best and brightest with glorious amenities. They will come and do nothing.



September 17 • 8:00 AM

Why Don’t We Have Pay Toilets in America?

Forty years ago, thanks to an organization founded by four high school friends, human rights beat out the free market—and now we can all pee for free.


September 17 • 6:32 AM

Do Conspiracy Theorists Feed on Unsuspecting Internet Trolls?

Not literally, but debunkers and satirists do fuel conspiracy theorists’ appetites.


September 17 • 6:00 AM

The Grateful Dig: An Archaeologist Excavates a Tie-Dyed Modern Stereotype

What California’s senior state archaeologist discovered in the ruins of a hippie commune.


September 17 • 4:00 AM

The Strong Symbolic Power of Emptying Pockets

Researchers find the symbolic act of emptying a receptacle can impact our behavior, and not for the better.


September 16 • 4:00 PM

Why Is LiveJournal Helping Russia Block a Prominent Critic of Vladimir Putin?

The U.S. blogging company is showing an error message to users inside Russia who try to read the blog of Alexei Navalny, a prominent politician and critic of the Russian government.


September 16 • 2:00 PM

Man Up, Ladies! … But Not Too Much

Too often, women are asked to display masculine traits in order to be successful in the workplace.



Follow us


How to Build a Better Election

Elimination-style voting is harder to fiddle with than majority rule.

Do Conspiracy Theorists Feed on Unsuspecting Internet Trolls?

Not literally, but debunkers and satirists do fuel conspiracy theorists' appetites.

3-D Movies Aren’t That Special

Psychologists find that 3-D doesn't have any extra emotional impact.

To Protect Against Meltdowns, Banks Must Map Financial Interconnections

A new model suggests looking beyond balance sheets, studying the network of investment as well.

Big Government, Happy Citizens?

You may like to talk about how much happier you'd be if the government didn't interfere with your life, but that's not what the research shows.

The Big One

One in three drivers in Brooklyn's Park Slope—at certain times of day—is just looking for parking. The same goes for drivers in Manhattan's SoHo. September/October 2014 new-big-one-3

Copyright © 2014 by Pacific Standard and The Miller-McCune Center for Research, Media, and Public Policy. All Rights Reserved.